Patents by Inventor Drew C. DENIGER

Drew C. DENIGER has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250216381
    Abstract: The present disclosure provides methods for identifying novel neoantigen-reactive T cell receptors (TCRs) by co-culturing a reporter T cell comprising a TCR expression cassette and an antigen presenting cell expressing a target neoantigen sequence and a matched human lymphocyte antigen (HLA) sequence. The present disclosure also provides novel neoantigen-reactive TCRs and the use thereof.
    Type: Application
    Filed: March 21, 2023
    Publication date: July 3, 2025
    Applicant: Alaunos Therapeutics, Inc.
    Inventors: Matthew R. COLLINSON-PAUTZ, Drew C. DENIGER, Guowei GU, Ana KORNGOLD, Beatriz A. SANTILLAN, Hao ZHAO
  • Publication number: 20210187028
    Abstract: Provided herein is a method of expanding clinically-relevant quantities of polyclonal ?? T cells that have anti-tumor, anti-viral, and anti-bacterial reactivity. Polyclonal ?? T cells can target a variety of tumors, including solid tumors as well as other conditions, such as viral and bacterial infections.
    Type: Application
    Filed: December 18, 2020
    Publication date: June 24, 2021
    Inventors: Laurence J.N. COOPER, Drew C. DENIGER
  • Publication number: 20180200299
    Abstract: Provided herein is a method of expanding clinically-relevant quantities of polyclonal ?? T cells that have anti-tumor, anti-viral, and anti-bacterial reactivity. Polyclonal ?? T cells can target a variety of tumors, including solid tumors as well as other conditions, such as viral and bacterial infections.
    Type: Application
    Filed: January 16, 2018
    Publication date: July 19, 2018
    Inventors: Laurence J.N. COOPER, Drew C. DENIGER
  • Publication number: 20160256487
    Abstract: Provided herein is a method of expanding clinically-relevant quantities of polyclonal ?? T cells that have anti-tumor, anti-viral, and anti-bacterial reactivity. Polyclonal ?? T cells can target a variety of tumors, including solid tumors as well as other conditions, such as viral and bacterial infections.
    Type: Application
    Filed: October 24, 2014
    Publication date: September 8, 2016
    Inventors: Laurence J.N. COOPER, Drew C. DENIGER